/ CompletedNot Applicable A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
100 Clinical Results associated with Perseid Therapeutics LLC
0 Patents (Medical) associated with Perseid Therapeutics LLC
100 Deals associated with Perseid Therapeutics LLC
100 Translational Medicine associated with Perseid Therapeutics LLC